CERT (Certara) Interest Income : $0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Certara Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Certara's interest income for the three months ended in Sep. 2024 was $0.0 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.

Certara Interest Income Historical Data

The historical data trend for Certara's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara Interest Income Chart

Certara Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Income

Get a 7-Day Free Trial

Certara Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Income	Get a 7-Day Free Trial															-	-	-	-	-

Certara Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Certara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

700:Germany

Address

100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540

Website

https://www.certara.com

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Executives

Patrick F Smith	officer: PRESIDENT, INTEGRATED DRUG DEV	C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Leif E Pedersen	officer: President, Software	10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Richard M. Traynor	officer: See Remarks	1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Eran Broshy	director	C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
John E Gallagher	officer: CHIEF FINANCIAL OFFICER	BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p.	10 percent owner	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight	director	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine	director	2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905